Everolimus + exemestane

1 paper1 finding

PubChem 6442177 PubChem 60198 ChEBI 68478 ChEBI 4953

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

1 lab in 1 country

Funders: Allergan and others
1 of 1 finding with company ties

Human trial1

Outcomes

Progression-free survival

upin humans1HR 0.45

1 study

Everolimus + exemestane increases progression-free survival in humans (Investigator-reviewed median PFS: 7.8 versus 3.2 months; HR 0.45, 95% CI 0.38–0.54. Central review: 11.0 versus 4.1 months; HR 0.38, 95% CI 0.31–0.48.).
Human trialPostmenopausal women with HR(+) advanced breast cancer recurring or progressing during or after nonsteroidal aromatase inhibitors; versus placebo plus exemestaneEverolimus 10 mg/day plus exemestane 25 mg/dayMedian 18-month follow-upfemales
Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis
Advances in therapy25 Oct 2013